Protective effects of the angiotensin II AT 2 receptor agonist compound 21 in ischemic stroke: A nose-to-brain delivery approach

Clinical Science

Volumn 132, Issue 5, 2018, Pages 581-593

  Bennion, Douglas M ^a   Jones, Chad H ^a   Dang, Alex N ^a   Isenberg, Jacob ^a   Graham, Justin T ^a   Lindblad, Lena ^b   Domenig, Oliver ^c   Waters, Michael F ^d   Poglitsch, Marko ^c   Sumners, Colin ^a   Steckelings, Ulrike Muscha ^e  

^a UNIVERSITY OF FLORIDA   (United States)

^b RISE RESEARCH INSTITUTES OF SWEDEN   (Sweden)

^c Attoquant Diagnostics GmbH   (Austria)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR AGONIST; COMPOUND 21; ENDOTHELIN 1; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG; ANGIOTENSIN 2 RECEPTOR; N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1-YLMETHYLPHENYL)-5-ISOBUTYLTHIOPHENE-2-SULFONAMIDE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BRAIN; BRAIN CORTEX; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; CORPUS STRIATUM; HEART PERFUSION; HEART RATE; HUMAN; MALE; NEUROPROTECTION; NONHUMAN; NOSE; PRIORITY JOURNAL; RAT; AGONISTS; ANIMAL; BLOOD; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; COMPLICATION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; METABOLISM; NOSE MUCOSA; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CEREBRAL INFARCTION; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; MALE; NASAL MUCOSA; NEUROPROTECTIVE AGENTS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 2; STROKE; SULFONAMIDES; THIOPHENES;

EID: 85046530952     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20180100     Document Type: Article

References (51)

1. Donnan, G.A., Fisher, M., Macleod, M. and Davis, S.M. (2008) Stroke. Lancet 371, 1612-1623, https://doi.org/10.1016/S0140-6736(08)60694-7
2. Norrving, B. and Kissela, B. (2013) The global burden of stroke and need for a continuum of care. Neurology 80, S5-S12, https://doi.org/10.1212/WNL.0b013e3182762397
3. Sarikaya, H., Ferro, J. and Arnold, M. (2015) Stroke prevention-medical and lifestyle measures. Eur. Neurol. 73, 150-157, https://doi.org/10.1159/000367652
4. Benjamin, E.J., Blaha, M.J., Chiuve, S.E., Cushman, M., Das, S.R., Deo, R. et al. (2017) Heart Disease and Stroke Statistics-2017 update: a report from the American Heart Association. Circulation 135, e146-603, https://doi.org/10.1161/CIR.0000000000000485
5. Minnerup, J., Schmidt, A., Albert-Weissenberger, C. and Kleinschnitz, C. (2013) Stroke: pathophysiology and therapy. Colloquium Series on Integrated Systems Physiology: From Molecule to Function to Disease, vol. 5, pp. 1-91, Morgan and Claypool Life Sciences
6. Candelario-Jalil, E. (2009) Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics. Curr. Opin. Investig. Drugs 10, 644-654
7. Fisher, M. and Saver, J.L. (2015) Future directions of acute ischaemic stroke therapy. Lancet Neurol. 14, 758-767, https://doi.org/10.1016/S1474-4422(15)00054-X
8. Heiss, W-D. (2010) The concept of the penumbra: can it be translated to stroke management? Int. J. Stroke 5, 290-295, https://doi.org/10.1111/j.1747-4949.2010.00444.x
9. Fisher, M. and Bastan, B. (2012) Identifying and utilizing the ischemic penumbra. Neurology 79, S79-S85, https://doi.org/10.1212/WNL.0b013e3182695814
10. Jauch, E.C., Saver, J.L., Adams, H.P., Bruno, A., Connors, J.J.B., Demaerschalk, B.M. et al. (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke J. Cereb. Circ. 44, 870-947, https://doi.org/10.1161/STR.0b013e318284056a
11. Del Zoppo, G.J., Saver, J.L., Jauch, E.C. and Adams, H.P. (2009) Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke J. Cereb. Circ. 40, 2945-2948, https://doi.org/10.1161/STROKEAHA.109.192535
12. Davis, S.M. and Donnan, G.A. (2009) 4.5 hours: the new time window for tissue plasminogen activator in stroke. Stroke 40, 2266-2267, https://doi.org/10.1161/STROKEAHA.108.544171
13. Appireddy, R.M.R., Demchuk, A.M., Goyal, M., Menon, B.K., Eesa, M., Choi, P. et al. (2015) Endovascular therapy for ischemic stroke. J. Clin. Neurol. 11, 1-8, https://doi.org/10.3988/jcn.2015.11.1.1
14. Saver, J.L., Goyal, M., van der Lugt, A., Menon, B.K., Majoie, C.B.L.M., Dippel, D.W. et al. (2016) Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA 316, 1279-1288, https://doi.org/10.1001/jama.2016.13647
15. McCarthy, C.A., Vinh, A., Broughton, B.R.S., Sobey, C.G., Callaway, J.K. and Widdop, R.E. (2012) Angiotensin II type 2 receptor stimulation initiated after stroke causes neuroprotection in conscious rats. Hypertension 60, 1531-1537
16. Arroja, M.M.C., Reid, E. and McCabe, C. (2016) Therapeutic potential of the renin angiotensin system in ischaemic stroke. Exp. Transl. Stroke Med. 8, 8, https://doi.org/10.1186/s13231-016-0022-1
17. Joseph, J.P., Mecca, A.P., Regenhardt, R.W., Bennion, D.M., Rodŕiguez, V., Desland, F. et al. (2014) The angiotensin type 2 receptor agonist Compound elicits cerebroprotection in endothelin-1 induced ischemic stroke. Neuropharmacology 81, 134-141, https://doi.org/10.1016/j.neuropharm.2014.01.044
18. Min, L.-J., Mogi, M., Tsukuda, K., Jing, F., Ohshima, K., Nakaoka, H. et al. (2014) Direct stimulation of angiotensin II type 2 receptor initiated after stroke ameliorates ischemic brain damage. Am. J. Hypertens. 27, 1036-1044, https://doi.org/10.1093/ajh/hpu015
19. McCarthy, C.A., Vinh, A., Miller, A.A., Hallberg, A., Alterman, M., Callaway, J.K. et al. (2014) Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats. PLoS ONE 9, e95762, https://doi.org/10.1371/journal.pone.0095762
20. Alhusban, A., Fouda, A.Y., null, Bindu Pillai, Ishrat, T., Soliman, S. and Fagan, S.C. (2015) Compound 21 is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke. J. Hypertens. 33, 170-180, https://doi.org/10.1097/HJH.0000000000000364
21. Schwengel, K., Namsolleck, P., Lucht, K., Clausen, B.H., Lambertsen, K.L., Valero-Esquitino, V. et al. (2016) Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice. J. Mol. Med. (Berl.) 94, 957-966, https://doi.org/10.1007/s00109-016-1406-3
22. Mateos, L., Perez-Alvarez, M.J. and Wandosell, F. (2016) Angiotensin II type-2 receptor stimulation induces neuronal VEGF synthesis after cerebral ischemia. Biochim. Biophys. Acta 1862, 1297-1308, https://doi.org/10.1016/j.bbadis.2016.03.013
23. Bennion, D.M., Isenberg, J.D., Harmel, A.T., DeMars, K., Dang, A.N., Jones, C.H. et al. (2017) Post-stroke angiotensin II type 2 receptor activation provides long-term neuroprotection in aged rats. PLoS ONE 12, e0180738, https://doi.org/10.1371/journal.pone.0180738
24. Fisher, M. (2011) New approaches to neuroprotective drug development. Stroke J. Cereb. Circ. 42, S24-S27, https://doi.org/10.1161/STROKEAHA.110.592394
25. Chao, J., Yang, L., Buch, S. and Gao, L. (2013) Angiotensin II increased neuronal stem cell proliferation: role of AT2R. PLoS ONE 8, e63488, https://doi.org/10.1371/journal.pone.0063488
26. Mestre, H., Cohen-Minian, Y., Daniel, Z.-F. and Ibarra, A. (2013) Pharmacological treatment of acute ischemic stroke. Available from: http://www.intechopen.com/books/neurodegenerative-diseases/pharmacological-treatment-of-acute-ischemic-stroke
27. Shraim, N., Mertens, B., Clinckers, R., Sarre, S., Michotte, Y. and Van Eeckhaut, A. (2011) Microbore liquid chromatography with UV detection to study the in vivo passage of compound 21, a non-peptidergic AT2 receptor agonist, to the striatum in rats. J. Neurosci. Methods 202, 137-142, https://doi.org/10.1016/j.jneumeth.2011.06.009
28. Pardeshi, C.V. and Belgamwar, V.S. (2013) Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin. Drug. Deliv. 10, 957-972, https://doi.org/10.1517/17425247.2013.790887
29. Djupesland, P.G., Messina, J.C. and Mahmoud, R.A. (2014) The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther. Deliv. 5, 709-733, https://doi.org/10.4155/tde.14.41
30. Jiang, Y., Li, Y. and Liu, X. (2015) Intranasal delivery: circumventing the iron curtain to treat neurological disorders. Expert Opin. Drug Deliv. 12, 1717-1725, https://doi.org/10.1517/17425247.2015.1065812
31. Reger, M.A., Watson, G.S., Green, P.S., Baker, L.D., Cholerton, B., Fishel, M.A. et al. (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J. Alzheimers Dis. 13, 323-331, https://doi.org/10.3233/JAD-2008-13309
32. Mischley, L.K., Leverenz, J.B., Lau, R.C., Polissar, N.L., Neradilek, M.B., Samii, A. et al. (2015) A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease. Mov. Disord. 30, 1696-1701, https://doi.org/10.1002/mds.26351
33. Kälviäinen, R. (2015) Intranasal therapies for acute seizures. Epilepsy Behav. 49, 303-306, https://doi.org/10.1016/j.yebeh.2015.04.027
34. Mecca, A.P., Regenhardt, R.W., O'Connor, T.E., Joseph, J.P., Raizada, M.K., Katovich, M.J. et al. (2011) Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp. Physiol. 96, 1084-1096, https://doi.org/10.1113/expphysiol.2011.058578
35. Bederson, J.B., Pitts, L.H., Tsuji, M., Nishimura, M.C., Davis, R.L. and Bartkowski, H. (1986) Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17, 472-476, https://doi.org/10.1161/01.STR.17.3.472
36. Garcia, J.H., Wagner, S., Liu, K.F. and Hu, X.J. (1995) Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 26, 627-634, https://doi.org/10.1161/01.STR.26.4.627
37. Li, H., Gao, Y., Grobe, J.L., Raizada, M.K., Katovich, M.J. and Sumners, C. (2007) Potentiation of the antihypertensive action of losartan by peripheral overexpression of the ANG II type 2 receptor. Am. J. Physiol. Heart Circ. Physiol. 292, H727-H735, https://doi.org/10.1152/ajpheart.00938.2006
38. Regenhardt, R.W., Desland, F., Mecca, A.P., Pioquinto, D.J., Afzal, A., Mocco, J. et al. (2013) Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke. Neuropharmacology 71, 154-163, https://doi.org/10.1016/j.neuropharm.2013.03.025
39. Bosnyak, S., Jones, E.S., Christopoulos, A., Aguilar, M.-I., Thomas, W.G. and Widdop, R.E. (2011) Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin. Sci. (Lond.) 121, 297-303
40. Owens, W.B. (2011) Blood pressure control in acute cerebrovascular disease. J. Clin. Hypertens. 13, 205-211, https://doi.org/10.1111/j.1751-7176.2010.00394.x
41. Hanson, L.R., Roeytenberg, A., Martinez, P.M., Coppes, V.G., Sweet, D.C., Rao, R.J. et al. (2009) Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J. Pharmacol. Exp. Ther. 330, 679-686, https://doi.org/10.1124/jpet.108.149807
42. Lioutas, V.-A., Alfaro-Martinez, F., Bedoya, F., Chung, C.-C., Pimentel, D.A. and Novak, V. (2015) Intranasal insulin and insulin-like growth factor 1 as neuroprotectants in acute ischemic stroke. Transl. Stroke Res. 6, 264-275, https://doi.org/10.1007/s12975-015-0409-7
43. Sommer, C.J. (2017) Ischemic stroke: experimental models and reality. Acta Neuropathol. (Berl.) 133, 245-261, https://doi.org/10.1007/s00401-017-1667-0
44. Mittal, D., Ali, A., Md, S., Baboota, S., Sahni, J.K. and Ali, J. (2014) Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 21, 75-86, https://doi.org/10.3109/10717544.2013.838713
45. Kassner, A. and Merali, Z. (2015) Assessment of blood-brain barrier disruption in stroke. Stroke J. Cereb. Circ. 46, 3310-3315, https://doi.org/10.1161/STROKEAHA.115.008861
46. Wolfe, T.R. and Braude, D.A. (2010) Intranasal medication delivery for children: a brief review and update. Pediatrics 126, 532-537, https://doi.org/10.1542/peds.2010-0616
47. Steckelings, U.M., de Kloet, A. and Sumners, C. (2017) Centrally mediated cardiovascular actions of the angiotensin II type 2 receptor. Trends Endocrinol. Metab. 28, 684-693, https://doi.org/10.1016/j.tem.2017.06.002
48. Regenhardt, R.W., Bennion, D.M. and Sumners, C. (2014) Cerebroprotective action of angiotensin peptides in stroke. Clin. Sci. (Lond.) 126, 195-205
49. Ruigrok, M.J.R. and de Lange, E.C.M. (2015) Emerging insights for translational pharmacokinetic and pharmacokinetic-pharmacodynamic studies: towards prediction of nose-to-brain transport in humans. AAPS J. 17, 493-505, https://doi.org/10.1208/s12248-015-9724-x
50. Leopold, D.A., Hummel, T., Schwob, J.E., Hong, S.C., Knecht, M. and Kobal, G. (2000) Anterior distribution of human olfactory epithelium. Laryngoscope 110, 417-421, https://doi.org/10.1097/00005537-200003000-00016
51. Djupesland, P.G., Mahmoud, R.A. and Messina, J.C. (2013) Accessing the brain: the nose may know the way. J. Cereb. Blood Flow Metab. 33, 793-794, https://doi.org/10.1038/jcbfm.2013.41